Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Incyte Corp (NASDAQ:INCY)

134.38
Delayed Data
As of May 26
 -4.03 / -2.91%
Today’s Change
71.75
Today|||52-Week Range
153.15
+34.02%
Year-to-Date
Kentucky Retirement Systems Insurance Trust Fund Buys Incyte Corp, TechnipFMC PLC, GG...
May 24 / GuruFocus News - Paid Partner Content
Incyte (INCY) Announces Positive Data on Enzyme Inhibitor
May 18 / Zacks.com - Paid Partner Content
Edward Owens Buys Abbott Labs, Sells Allergan, Amgen, Aetna
May 23 / GuruFocus News - Paid Partner Content
Concert Pharma Falls After Clinical Hold on Hair Loss Drug
May 18 / Zacks.com - Paid Partner Content
Company News for May 19, 2017
May 19 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close138.41
Today’s open138.46
Day’s range132.65 - 139.49
Volume2,366,454
Average volume (3 months)2,408,134
Market cap$28.3B
Dividend yield--
Data as of 3:59pm ET, 05/26/2017

Growth & Valuation

Earnings growth (last year)+1,700.00%
Earnings growth (this year)-235.32%
Earnings growth (next 5 years)+64.80%
Revenue growth (last year)+46.70%
P/E ratioNM
Price/Sales17.60
Price/Book62.31

Competitors

 Today’s
change
Today’s
% change
ALXNAlexion Pharmaceutic...-0.80-0.81%
VRTXVertex Pharmaceutica...+1.32+1.11%
ZTSZoetis Inc+0.03+0.05%
BAXBaxter International...-0.50-0.85%
Data as of 4:14pm ET, 05/26/2017

Financials

Next reporting dateAugust 3, 2017
EPS forecast (this quarter)$0.01
Annual revenue (last year)$1.1B
Annual profit (last year)$104.2M
Net profit margin9.43%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman, President &
Chief Executive Officer
Hervé Hoppenot
Chief Financial Officer &
Executive Vice President
David W. Gryska
Corporate headquarters
Wilmington, Delaware

Forecasts